Connect with us

Press Release

Theriva Biologics Receives Fast Track Designation From FDA For VCN-01 For Treating Metastatic Pancreatic Cancer

Published

on

–News Direct–

By Kyle Anthony, Benzinga

Theriva Biologics (AMEX: TOVX) is an immuno-oncology company developing oncolytic viruses, otherwise known as cancer cell-infecting viruses, to overcome the protective barrier surrounding solid tumors and selectively kill tumor cells. As a company engaged in developing differentiated clinical-stage therapeutics, Therivas mission is to change patient outcomes by working to improve the current standard of care and transform the cancer therapy landscape.

The firms management and scientific advisory board is comprised of determined and experienced leaders who are committed to offering patients with difficult-to-treat cancers the chance of a longer life. The company recently achieved a significant milestone as the U.S. FDA granted Fast Track Designation (FTD) to its candidate VCN-01 to improve progression-free survival and overall survival in patients with metastatic pancreatic adenocarcinoma. Previously, the FDA granted orphan drug designation to VCN-01 for treatment of pancreatic ductal adenocarcinoma (PDAC).

Company Background

Founded in 2001 and operating as Synthetic Biologics from 2012, the company was previously focused on developing biologic and drug candidates for various indications, including infectious diseases and gastrointestinal disorders. The company rebranded to Theriva Biologics in September 2022 to reflect its evolving focus on oncolytic viruses and cancer therapies. Regarding the impetus behind the firms rebranding, Steven A. Shallcross, Chief Executive Officer of Theriva Biologics, said, The rebranding solidifies our strategic transformation and reflects our sharpened focus on advancing unique, oncolytic viruses optimized for IV administration. We continue to build on the incredible progress made to date and are diligently advancing our oncolytic adenovirus pipeline. This includes lead clinical-stage program VCN-01, designed to break down the tumor stroma, and preclinical-stage program VCN-11, leveraging our proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. These two differentiated programs are intended to improve the anti-tumor effect of the oncolytic virus, co-administered chemotherapies and/or immuno-oncology therapeutics. Together, VCN-01 and VCN-11 position Theriva at the forefront of oncolytic virus development. We are excited about Therivas path towards strategic growth, renewed corporate strategy and remain on track to deliver on upcoming value-driving milestones.

Theriva Biologics Pipeline

As Steven A. Shallcrosss preceding quote suggests, Theriva Biologics' leading clinical-stage program, VCN-01, has displayed promise as a treatment solution. Presently, VCN-01 is part of an ongoing phase 2 clinical trial, entitled VIRAGE, where it is being tested in combination with standard-of-care chemotherapy for patients with pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer. VCN-01 was also administered with the checkpoint inhibitor durvalumab (an FDA-approved immunotherapy for cancer) in a phase 1 study in patients with head and neck cancers and is currently being evaluated in combination with huCART-meso cells cells manufactured using a patients own white blood cells, which are modified to target cancer cells or cells that help cancer to grow in an investigator-sponsored study in patients with either pancreatic cancer or ovarian cancer.

Beyond VCN-01, Theriva Biologics is also developing SYN-004 (ribaxamase), which is aligned with the companys oncology focus and seeks to mitigate adverse outcomes for patients who will undergo bone marrow transplant (allogeneic hematopoietic cell transplantation) to treat hematologic cancers. 80% to 90% of these patients will be treated with an intravenous -lactam antibiotic, and this antibiotic treatment has been strongly associated with increased incidence and severity of acute graft-vs-host disease (aGVHD), vancomycin-resistant Enterococci (VRE) infection and Clostridioides difficile infection (CDI). Preventing one or all of these outcomes by SYN-004 co-administration may significantly improve treatment outcomes and reduce patient mortality.

VCN-01 Receives Fast Track Designation By The U.S. FDA

Theriva Biologics achieved a significant milestone as the FDA granted Fast Track Designation (FTD) to VCN-01. This designation, in combination with gemcitabine and nab-paclitaxel standard-of-care chemotherapy drugs is aimed at improving progression-free survival and overall survival in patients with metastatic pancreatic cancer. This recognition underscores Theriva Biologics' commitment to advancing cancer treatment and the potential of VCN-01 in this field.

Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer across the U.S. and other parts of the world is one of the factors driving the need for drugs used in its treatment. According to research published by Fortune Business Insights, the global pancreatic cancer treatment market size was $2.86 billion in 2023 and is projected to grow from $3.30 billion in 2024 to $10.69 billion by 2032.

Attaining FTD is a seminal achievement for pharmaceutical drug companies, as the designation is designed to help treatments reach patients faster by facilitating the development and expediting the review of therapies with the potential to treat serious conditions and fill an unmet medical need. Benefits of FTD to programs include early and frequent interactions with the FDA during the clinical development process, and if relevant criteria are met, the FDA may also review portions of a marketing application before the sponsor submits the complete application.

Regarding Theriva Biologics receiving the FTD, Shallcross said, The FDAs decision to grant FTD to VCN-01 highlights the urgent need for new treatment options for PDAC, which accounts for the 4th highest cause of cancer-associated deaths in the US and Europe. VIRAGE, our Phase 2b trial evaluating VCN-01 in metastatic PDAC continues to progress, with enrollment expected to be completed in the third quarter of 2024. FTD is an important step that furthers our ability to expedite the review of and build upon the compelling clinical data that underscores VCN-01s multiple modes of action and therapeutic potential in combination with chemotherapy or immunotherapy. We will continue to deliver on our mission to advance new therapeutic options for these patients.

Based on the strength of the science and its relevance, VIRAGE was accepted for presentation as a trial-in-progress poster at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, IL, from May 31-June 4.

The Path Forward

Theriva Biologics' approach to cancer treatment differentiates it from its peers, potentially placing the company in a unique market position. As incidences of pancreatic cancer continue to rise globally, drug treatment options, such as VCN-01, will likely rise in demand. With VCN-01 receiving FTD from the U.S. FDA, this milestone speaks to the drug's efficacy and long-run potential. As such, the benefit that Theriva Biologics provides and the value proposition the firm espouses could continue to grow and have increased industry resonance.

Featured photo by National Cancer Institute on Unsplash.

Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Benzinga

+1 877-440-9464

info@benzinga.com

Company Website

http://www.benzinga.com

View source version on newsdirect.com: https://newsdirect.com/news/theriva-biologics-receives-fast-track-designation-from-fda-for-vcn-01-for-treating-metastatic-pancreatic-cancer-427600911

Benzinga

comtex tracking

COMTEX_453481266/2655/2024-06-07T08:44:04

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

2027 Federal Withholding Tax Tables Announced by American Tax Service

Published

on

American Tax Service has published an updated guide to the 2027 federal withholding tax tables, explaining how employers calculate federal income tax deductions from employee paychecks using IRS withholding methods and Form W-4 information.

Estero, FL, United States, 21st Nov 2026 – American Tax Service has updated its educational coverage of the 2027 federal tax withholding tables following the Internal Revenue Service’s release of a draft Publication 15-T, Federal Income Tax Withholding Methods.

2027 Federal Withholding Tax Tables Announced by American Tax Service

The updated resource, 2027 Federal Tax Withholding Tables, explains how employers, payroll departments, employees, and retirees can prepare for changes to federal income tax withholding during the 2027 tax year.

The IRS posted its draft 2027 Publication 15-T on November 12, 2026. The document is an early release draft, not the final publication. The IRS also provided the 2027 withholding tables in an accompanying Excel file rather than incorporating them into the initial draft PDF.

IRS Releases Preliminary 2027 Payroll Withholding Guidance

Publication 15-T explains the methods employers and other payers use to calculate federal income tax withholding from wages and certain periodic pension and annuity payments.

The publication covers two primary calculation methods:

  • Wage Bracket Method for payroll systems using wage ranges.
  • Percentage Method for calculating withholding using adjusted wages and applicable rates.

Employers use these methods along with employee information provided on Form W-4. The correct calculation depends on filing status, payroll frequency, wages, and any additional withholding adjustments.

The IRS cautions that draft publications are subject to change. Employers should review the final 2027 Publication 15-T before relying on the updated procedures for payroll processing.

2027 Tax Brackets and Payroll Withholding

The 2027 federal tax brackets have also been announced, with seven marginal income tax rates continuing at 10%, 12%, 22%, 24%, 32%, 35%, and 37%.

The IRS increased the income thresholds for the 2027 tax year to account for inflation. The standard deduction for married couples filing jointly increases to $33,200, while the standard deduction for single taxpayers increases to $16,600.

American Tax Service provides additional information about the 2027 federal tax brackets and the 2027 federal tax tables for married filing jointly.

These annual tax adjustments are important because withholding calculations are designed to account for the applicable tax structure and deductions.

Form W-4 and Employee Withholding Adjustments

Form W-4, Employee’s Withholding Certificate, provides employers with information used to calculate federal income tax withholding.

Employees can review their withholding after major financial changes, including marriage, divorce, a new job, a salary increase, additional income, or retirement.

Married employees with two incomes should pay particular attention to their withholding elections. If both spouses work, incorrect W-4 information can result in insufficient federal income tax withholding throughout the year.

American Tax Service also maintains a guide to the 2026 federal withholding tax tables, which remain useful for understanding the current payroll withholding system.

Payroll Preparation for the 2027 Tax Year

Employers should prepare to update payroll systems when the final 2027 withholding guidance becomes available. Businesses that calculate payroll manually should also review the appropriate IRS wage bracket and percentage methods.

Federal income tax withholding is separate from Social Security and Medicare payroll taxes. Employers must continue to calculate these payroll taxes under their applicable requirements.

Employees and retirees can also review the 2026 federal tax tables to better understand how taxable income and filing status affect their federal income tax calculations.

About American Tax Service

American Tax Service provides educational tax information covering federal income tax brackets, withholding tables, IRS forms, deductions, tax credits, retirement income, and tax filing requirements. Its resources are designed to help taxpayers, employees, retirees, and employers better understand federal tax rules and prepare for upcoming filing and payroll changes.

Media Contact

Organization: American Tax Service

Contact Person: Frank Ellis

Website: https://americantaxservice.org/

Email: Send Email

Address: 20020 Barletta Lane

City: Estero

State: FL

Country: United States

Release id: 50944

View source version on King Newswire:
2027 Federal Withholding Tax Tables Announced by American Tax Service

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

A New Approach to Retirement Planning – Jim Capuano’s Newly Released Book Helps Americans Protect Their Retirement Savings

Published

on

United States, 21st Nov 2026 – Financial services professional and IRMAA-Certified Planner Jim Capuano has released his book, The Great American Retirement Myth. The new book is an eye-opening retirement planning guide that debunks common myths, demystifies industry jargon, and equips readers with the tools and techniques to protect and grow their wealth in retirement. It offers an in-depth look at how assets should be structured, taxed, and distributed.

Paperback Expert

The Great American Retirement Myth is a comprehensive book that exposes common financial planning practices that leave retirees with hefty tax bills, lower income, and less spending power than their savings suggest. It helps readers understand that the people they trust to manage their money often follow industry practices that generate more profit for their firms and don’t necessarily work in the retiree’s favor. By simplifying complex financial concepts and equipping readers with the knowledge to make informed decisions, the book helps Americans from all walks of life understand the shifting retirement landscape, navigate the system, and ultimately protect and grow their assets throughout retirement. Whether it’s retirement savings, Medicare, or Social Security, the book invites readers to reconsider familiar advice and approach financial planning with a clearer understanding of their options.

The Great American Retirement Myth by Jim Capuano

Jim Capuano is an IRMAA-Certified Planner who has applied his expertise to clients in the financial services industry for nearly two decades. He is passionate about helping individuals, families, and organizations keep what they earn and grow it. He founded and leads The Integrity Life Brokerage. He spent years working with consumers in the retail sector and with financial advisors in the wholesale market, gaining experience on both sides of the financial services industry.

With his thought-provoking new book, he invites American retirees to broaden their understanding of retirement-related financial decisions by learning how the industry operates on the inside. After many years of developing and refining his methods, his work now focuses primarily on insurance-based financial strategies and retirement planning.

Jim Capuano, IRMAACP™, is available for interviews.

Title: The Great American Retirement Myth

Author: Jim Capuano, IRMAACP™

Contact: Michael DeLon 

Company:  Paperback Expert 

Email: press@PaperbackExpert.com  

Phone Number:  (501) 404-8690

About Jim Capuano: https://theintegritylb.com/our-team

Availability: Amazon.com

Book Preview: https://www.amazon.com/dp/B0HPMMVXG2

Media Contact

Organization: Paperback Expert

Contact Person: Michael DeLon

Website: https://paperbackexpert.com/

Email: Send Email

Contact Number: +15014048690

Country: United States

Release id: 50999

View source version on King Newswire:
A New Approach to Retirement Planning – Jim Capuano’s Newly Released Book Helps Americans Protect Their Retirement Savings

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Face the IRS with Confidence Daniel Cotts’s Newly Released Book Reveals Complete Tax Resolution Strategies

Published

on

United States, 21st Nov 2026 – Tax attorney and tax resolution specialist Daniel Cotts has released his book, The IRS Bouncer: A Survivor—Your Last Line of Defense Against the IRS. The new book is a valuable financial guide that helps individuals and small businesses achieve complete tax resolution and put measures in place to avoid future IRS trouble. Beyond professional challenges, the book also examines the immense personal cost of tax debt.

Paperback Expert

The IRS Bouncer is an empowering book that equips readers with the knowledge, confidence, tools, and strategies to face the IRS and negotiate resolutions that work in taxpayers’ favor. It brings together practical explanations of IRS enforcement procedures, legal resolution strategies, and real-world client experiences to address problems that affect individuals and businesses nationwide. It not only takes a deep dive into installment agreements, offers in compromise, partial payment installment agreements, and more, but also highlights powerful options beyond conventional repayment arrangements. The author also shares his story of overcoming personal adversity after a near-fatal accident left him in a coma, connecting his experience with the challenges faced by taxpayers dealing with mounting liabilities, intimidating correspondence, and aggressive collection measures.

The IRS Bouncer by Daniel Cotts

Daniel Cotts is a seasoned tax attorney passionate about helping American families, businesses, and individuals achieve complete tax resolution. As the founder of Cotts Law, he is known for resolving serious tax disputes and guiding clients through audits, liens, levies, and garnishments. With a Juris Doctor and a Master of Accountancy, he is also licensed to practice before the United States Tax Court, giving him a competitive advantage and enabling him to understand the American tax system from the inside out.

After graduating from Southern Methodist University with a Master of Laws in Taxation, he proactively educates the public about tax issues and their legal rights when dealing with the IRS. Through his new book, he helps readers understand their options, choose the right legal representation, and regain financial control after resolution.

Daniel Cotts is available for interviews.

Title: The IRS Bouncer: A Survivor—Your Last Line of Defense Against the IRS

Author: Daniel Cotts, Tax Attorney

Contact: Michael DeLon 

Company:  Paperback Expert 

Email: press@PaperbackExpert.com  

Phone Number:  (501) 404-8690

About Daniel Cotts: https://cottslaw.com/about

Availability: Amazon.com

Book Preview: https://www.amazon.com/dp/B0HM8J296D

Media Contact

Organization: Paperback Expert

Contact Person: Michael DeLon

Website: https://paperbackexpert.com/

Email: Send Email

Contact Number: +15014048690

Country: United States

Release id: 51000

View source version on King Newswire:
Face the IRS with Confidence Daniel Cotts’s Newly Released Book Reveals Complete Tax Resolution Strategies

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST